Esperion Therapeutics (ESPR) Tops Q4 EPS by 50c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. DOX
4. AMGN
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Esperion Therapeutics (ESPR) Tops Q4 EPS by 50c

Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

February 22, 2022 7:00 AM EST

 Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022

U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew 12% Sequentially to $12.2 Million in the Fourth Quarter 2021 and Over 200% for the Full Year 2021

 Prescriptions Grew 9% During the Quarter; Approximately 70,000 Patients Have Filled a Prescription for NEXLETOL Tablets or NEXLIZET Tablets Since Launch

 Strengthened Capital Position in Fourth Quarter 2021 with $209 Million Financing Securing Path to CLEAR Outcomes Topline and Beyond

ANN ARBOR, Mich., Feb. 22,... More